PAOLA-1/ENGOT-ov251 trialVeröffentlicht am: 28. Sept. 2019
ESMO 2019: Ovarian cancer – women benefit from maintenance combined targeted therapy
New data show that a more intensive maintenance regimen with olaparib added to bevacizumab prolongs survival in an all-comers population, with and without a BRCA mutation.
